GLP-1 receptor agonists and uses thereof

A compound of Formula I

• or a pharmaceutically acceptable salt thereof, wherein
• each R1 is independently halogen, —CN, —C1-3alkyl, or —OC1-3alkyl, wherein the alkyl of C1-3alkyl and OC1-3alkyl is substituted with 0 to 3 F atoms;
• m is 0, 1, 2, or 3;
• each R2 is independently F, Cl, or —CN;
• p is 0, 1 or 2;
• each R3 is independently F, —OH, —CN, —C1-3alkyl, —OC1-3alkyl, or —C3-4cycloalkyl, or 2 R3s may together cyclize to form —C3-4spirocycloalkyl, wherein the alkyl of C1-3alkyl and OC1-3alkyl, cycloalkyl, or spirocycloalkyl may be substituted as valency allows with 0 to 3 F atoms and with 0 to 1 —OH;
• q is 0, 1, or 2;
• Y is CH or N;
• R4 is —C1-3alkyl, —C0-3alkylene-C3-6cycloalkyl, —C0-3alkylene-R5, or —C1-3alkylene-R6, wherein said alkyl may be substituted as valency allows with 0 to 3 substituents independently selected from 0 to 3 F atoms and 0 to 1 substituent selected from —C0-1alkylene-CN, —C0-1alkylene-ORO, and —N(RN)2, and
• wherein said alkylene and cycloalkyl may be independently substituted as valency allows with 0 to 2 substituents independently selected from 0 to 2 F atoms and 0 to 1 substituent selected from —C0-1alkylene-CN, —C0-1alkylene-ORO, and —N(RN)2;
• R5 is a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl may be substituted with 0 to 2 substituents as valency allows independently selected from:
• 0 to 1 oxo (═O),
• 0 to 1 —CN,
• 0 to 2 F atoms, and
• 0 to 2 substituents independently selected from —C1-3alkyl and —OC1-3alkyl, wherein the alkyl of C1-3alkyl and OC1-3alkyl may be substituted with 0 to 3 substituents as valency allows independently selected from:
• 0 to 3 F atoms,
• 0 to 1 —CN, and
• 0 to 1 —ORO;
• R6 is a 5- to 6-membered heteroaryl, wherein said heteroaryl may be substituted with 0 to 2 substituents as valency allows independently selected from:
• 0 to 2 halogens,
• 0 to 1 substituent selected from —ORO and —N(RN)2, and
• 0 to 2 —C1-3alkyl, wherein the alkyl may be substituted with 0 to 3 substituents as valency allows independently selected from:
• 0 to 3 F atoms, and
• 0 to 1 —ORO;
• each RO is independently H, or —C1-3alkyl, wherein C1-3alkyl may be substituted with 0 to 3 F atoms;
• each RN is independently H, or —C1-3alkyl;
• Z1 is CH or N;
• Z2 and Z3 are each independently —CRZ or N, provided that when Z1 or Z3 is N, Z2 is —CRZ;
• and
• each RZ is independently H, F, Cl, or —CH3.